Article

Flinn, based in Vienna, has raised $20 million in funding to develop AI tools for automating regulatory and quality processes in medtech and pharmaceuticals. The funding round was led by HV Capital, with backing from BHI - Bertelsmann Healthcare Investments and existing investors. The investment aims to expand Flinn’s platform across the entire product lifecycle and support international growth, particularly in the US market.